{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2024"],"condition":["Colon Cancer","Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colon Cancer","Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/7898"],"location":["United States"],"study_start_month":["7"],"keyword":["Irinotecan","Cetuximab","Adagrasib"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer","description":"To find the recommended dose of MRTX849 that can be given in combination with cetuximab and irinotecan to patients with colorectal cancer that have a mutation (genetic change) called KRAS G12C.","dates":{"creation":"2024-07-15"},"accession":"7898","cross_references":{"ClinicalTrials___gov":["NCT05722327"]}}